BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29211034)

  • 1. Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.
    McRae N; Forgan L; McNeill B; Addinsall A; McCulloch D; Van der Poel C; Stupka N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-ADAMTS1 treatment relieved muscle dysfunction and fibrosis in dystrophic mice.
    Wang Y; Xiao Y; Zheng Y; Yang L; Wang D
    Life Sci; 2021 Sep; 281():119756. PubMed ID: 34175316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic reduction of the extracellular matrix protein versican attenuates inflammatory cell infiltration and improves contractile function in dystrophic mdx diaphragm muscles.
    McRae NL; Addinsall AB; Howlett KF; McNeill B; McCulloch DR; Stupka N
    Sci Rep; 2020 Jul; 10(1):11080. PubMed ID: 32632164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versican processing by a disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats proteinases-5 and -15 facilitates myoblast fusion.
    Stupka N; Kintakas C; White JD; Fraser FW; Hanciu M; Aramaki-Hattori N; Martin S; Coles C; Collier F; Ward AC; Apte SS; McCulloch DR
    J Biol Chem; 2013 Jan; 288(3):1907-17. PubMed ID: 23233679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Dystrophic
    Addinsall AB; Forgan LG; McRae NL; Kelly RW; McDonald PL; McNeill B; McCulloch DR; Stupka N
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32156081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.
    Gibertini S; Zanotti S; Savadori P; Curcio M; Saredi S; Salerno F; Andreetta F; Bernasconi P; Mantegazza R; Mora M
    Cell Tissue Res; 2014 May; 356(2):427-43. PubMed ID: 24723230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle.
    Gosselin LE; Williams JE; Deering M; Brazeau D; Koury S; Martinez DA
    Muscle Nerve; 2004 Nov; 30(5):645-53. PubMed ID: 15389721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential calcineurin signalling activity and regeneration efficacy in diaphragm and limb muscles of dystrophic mdx mice.
    Stupka N; Michell BJ; Kemp BE; Lynch GS
    Neuromuscul Disord; 2006 May; 16(5):337-46. PubMed ID: 16621557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers.
    Miyazaki D; Nakamura A; Fukushima K; Yoshida K; Takeda S; Ikeda S
    Hum Mol Genet; 2011 May; 20(9):1787-99. PubMed ID: 21320869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.
    Fontelonga TM; Jordan B; Nunes AM; Barraza-Flores P; Bolden N; Wuebbles RD; Griner LM; Hu X; Ferrer M; Marugan J; Southall N; Burkin DJ
    Hum Mol Genet; 2019 Jul; 28(13):2120-2132. PubMed ID: 30806670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.
    Xu D; Zhao L; Jiang J; Li S; Sun Z; Huang X; Li C; Wang T; Sun L; Li X; Jiang Z; Zhang L
    J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1306-1320. PubMed ID: 32869445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of CCAAT/Enhancer-Binding Protein β Expression With the Phosphodiesterase Inhibitor Isobutylmethylxanthine Improves Myoblast Engraftment Into Dystrophic Muscle.
    Lala-Tabbert N; Fu D; Wiper-Bergeron N
    Stem Cells Transl Med; 2016 Apr; 5(4):500-10. PubMed ID: 26941360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of compensation afforded by accessory muscles of breathing leads to respiratory system compromise in the mdx mouse model of Duchenne muscular dystrophy.
    O'Halloran KD; Maxwell MN; Marullo AL; Hamilton CP; Ó Murchú SC; Burns DP; Mahony CM; Slyne AD; Drummond SE
    J Physiol; 2023 Oct; 601(19):4441-4467. PubMed ID: 37688347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle-specific deletion of SLK/Stk2 enhances p38 activity and myogenesis in mdx mice.
    Pryce BR; Labrèche C; Hamoudi D; Abou-Hamad J; Al-Zahrani KN; Hodgins JJ; Boulanger-Piette A; Bossé S; Balog-Alvarez C; Frénette J; Ardolino M; Kornegay JN; Sabourin LA
    Biochim Biophys Acta Mol Cell Res; 2021 Feb; 1868(2):118917. PubMed ID: 33259860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse.
    McCarthy JJ; Esser KA; Andrade FH
    Am J Physiol Cell Physiol; 2007 Jul; 293(1):C451-7. PubMed ID: 17459947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the normal content of sulfhydryl groups attributable to sparing from dystrophic pathology in dystrophin-deficient muscles?
    Niebrój-Dobosz I; Fidziańska A; Glinka Z; Hausmanowa-Petrusewicz I
    Folia Neuropathol; 2002; 40(3):143-50. PubMed ID: 12572920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.